Send to

Choose Destination
Res Pract Thromb Haemost. 2020 Jan 29;4(2):318-325. doi: 10.1002/rth2.12301. eCollection 2020 Feb.

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.

Author information

Child Health Evaluative Sciences The Hospital for Sick Children Toronto ON Canada.
Division of Hematology/Oncology The Hospital for Sick Children Toronto ON Canada.
Department of Pediatrics Faculty of Medicine University of Toronto Toronto ON Canada.
Institute of Health Policy, Management and Evaluation the Dalla Lana School of Public Health University of Toronto Toronto ON Canada.
Division of Pediatric Hematology/Oncology IWK Health Centre Halifax NS Canada.
Centre de l'hémophilie de l'est du Québec Hôpital de l'Enfant-Jésus Université Laval Québec QC Canada.
Division of Hematology/Oncology Department of Pediatrics CHU Sainte-Justine Montreal QC Canada.
Division of Pediatric Hematology/Oncology Children's Hospital of Eastern Ontario University of Ottawa Ottawa ON Canada.
Health Sciences North Sudbury ON Canada.
Division of Hematology/Oncology Thunder Bay Regional Cancer Care Thunder Bay ON Canada.
Department of Pediatrics McMaster Children's Hospital McMaster University Hamilton ON Canada.
Department of Pediatrics and Child Health University of Manitoba Winnipeg MB Canada.
Saskatchewan Bleeding Disorders Program Royal University Hospital Saskatoon SK Canada.
Section of Pediatric Hematology Department of Pediatrics University of Calgary and Alberta Children's Hospital Calgary AB Canada.
Division of Hematology/Oncology/BMT Department of Pediatrics UBC & BC Children's Hospital Vancouver BC Canada.
Division of Rheumatology The Hospital for Sick Children Toronto ON Canada.



Standard of care for persons with severe hemophilia A includes regular replacement of factor VIII (FVIII). Prophylaxis regimens using standard half-life (SHL) FVIII concentrates, while effective, are costly and require frequent intravenous infusions.


This study evaluated the adherence of 56 boys with severe hemophilia A to tailored, frequency-escalated prophylaxis with an SHL recombinant FVIII concentrate.


We reviewed the factor infusion and bleeding logs of study subjects. Adherence to the prescribed regimen was calculated on a weekly basis, and bleeding rates were determined from self/proxy-reported bleeding logs. The primary outcome was adherence to the prescribed prophylaxis regimen.


The median (range of values [ROV]) weekly adherence to prophylaxis was 85.7% (37.4%-99.8%). The median (ROV) adherent weeks on steps 1 (weekly), 2 (twice weekly), and 3 (alternate-day) were 92.9% (50%-100%), 80.3 (32%-96%), and 72.6% (14%-98%); relative to step 1, subjects were less likely to be adherent on steps 2 and 3 (P < 0.00). On step 1, our cohort had higher adherence than previously reported rates. The median (ROV) adherence to the breakthrough bleeding protocol was 47.1% (0%-100%). At any given time, bleeding risk was reduced by 15% for each 10% increase in adherence during the preceding 12 weeks (hazard ratio, 0.85; 95% confidence interval, 0.81-0.90).


This cohort had high rates of adherence to the prescribed prophylaxis regimen. Initiating prophylaxis with once-weekly infusions facilitated adherence to the prophylaxis regimen in this cohort of boys with severe hemophilia A started on primary prophylaxis at a very young age.


bleeding; factor VIII; hemophilia A; prophylaxis; treatment adherence and compliance

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center